BioCentury | Oct 30, 2006
Company News

CoLucid management update

...Dynogen Pharmaceuticals Inc.; and Barbara Dearry as director of operations, formerly director of operations at Xsira Pharmaceuticals...
BioCentury | Jul 18, 2005
Clinical News

Adenosine: Phase II start

...Xsira will begin in the fall the double-blind, placebo-controlled, dose-escalation Phase II trial (ADO-122). Xsira Pharmaceuticals...
BioCentury | May 2, 2005
Product Development

Unfinished business

...Roger Blevins, president and CEO of Xsira Pharmaceuticals Inc., is going back to his roots to develop...
...the technology to develop our own drugs." Thus, In January, Xsira changed its name from Norak...
...variety of procedures. Xsira plans to market the product in the U.S. To do so, Xsira...
BioCentury | Apr 18, 2005
Company News

Xsira Pharmaceuticals Inc., Harbor-UCLA Medical Center deal

...rights from the center to develop adenosine to treat post-operative pain. Terms were not disclosed. Xsira Pharmaceuticals...
BioCentury | Mar 14, 2005
Company News

Molecular Devices, Xsira Pharmaceuticals Inc. deal

...acquired the assets of Xsira's Transfluor imaging technology for $11 million in cash. Xsira (formerly Norak...
...a license to Transfluor that it received from MDCC. Molecular Devices Corp. (MDCC), Sunnyvale, Calif. Xsira Pharmaceuticals...
BioCentury | Nov 8, 2004
Company News

Norak, AstraZeneca deal

...Under a second license agreement, AZN will use Norak's Transfluor fluorescence-based GPCR technology to advance lead...
...GPCR technology to advance lead compounds discovered under the companies' 2002 high throughput screening deal. Norak...
BioCentury | Oct 25, 2004
Company News

Curis, Norak deal

...technology to develop cell lines expressing selected receptors from CRIS. Financial terms were not disclosed. Norak...
...the Transfluor technology from Duke University (Durham, N.C.) in 1999. Curis Inc. (CRIS), Cambridge, Mass. Norak...
BioCentury | Oct 18, 2004
Company News

Norak, Purdue Pharma deal

...develop cell lines that express a G protein-coupled receptor (GPCR) orphan target supplied by Purdue. Norak...
...lines, which it will use to screen Purdue's compound libraries. Financial terms were not disclosed. Norak...
BioCentury | Oct 13, 2004
Company News

Norak, Purdue GPCR deal

...technology to develop cell lines expressing an orphan GPCR target from Purdue Pharma (Stamford, Conn.). Norak...
BioCentury | Sep 13, 2004
Company News

Norak, Roche deal

...The companies extended for a second year their 2002 deal under which Norak provides ROCZ with...
...with its Transfluor cell lines expressing GPCR targets of interest (see BioCentury, Oct. 7, 2002). Norak...
Items per page:
1 - 10 of 52
BioCentury | Oct 30, 2006
Company News

CoLucid management update

...Dynogen Pharmaceuticals Inc.; and Barbara Dearry as director of operations, formerly director of operations at Xsira Pharmaceuticals...
BioCentury | Jul 18, 2005
Clinical News

Adenosine: Phase II start

...Xsira will begin in the fall the double-blind, placebo-controlled, dose-escalation Phase II trial (ADO-122). Xsira Pharmaceuticals...
BioCentury | May 2, 2005
Product Development

Unfinished business

...Roger Blevins, president and CEO of Xsira Pharmaceuticals Inc., is going back to his roots to develop...
...the technology to develop our own drugs." Thus, In January, Xsira changed its name from Norak...
...variety of procedures. Xsira plans to market the product in the U.S. To do so, Xsira...
BioCentury | Apr 18, 2005
Company News

Xsira Pharmaceuticals Inc., Harbor-UCLA Medical Center deal

...rights from the center to develop adenosine to treat post-operative pain. Terms were not disclosed. Xsira Pharmaceuticals...
BioCentury | Mar 14, 2005
Company News

Molecular Devices, Xsira Pharmaceuticals Inc. deal

...acquired the assets of Xsira's Transfluor imaging technology for $11 million in cash. Xsira (formerly Norak...
...a license to Transfluor that it received from MDCC. Molecular Devices Corp. (MDCC), Sunnyvale, Calif. Xsira Pharmaceuticals...
BioCentury | Nov 8, 2004
Company News

Norak, AstraZeneca deal

...Under a second license agreement, AZN will use Norak's Transfluor fluorescence-based GPCR technology to advance lead...
...GPCR technology to advance lead compounds discovered under the companies' 2002 high throughput screening deal. Norak...
BioCentury | Oct 25, 2004
Company News

Curis, Norak deal

...technology to develop cell lines expressing selected receptors from CRIS. Financial terms were not disclosed. Norak...
...the Transfluor technology from Duke University (Durham, N.C.) in 1999. Curis Inc. (CRIS), Cambridge, Mass. Norak...
BioCentury | Oct 18, 2004
Company News

Norak, Purdue Pharma deal

...develop cell lines that express a G protein-coupled receptor (GPCR) orphan target supplied by Purdue. Norak...
...lines, which it will use to screen Purdue's compound libraries. Financial terms were not disclosed. Norak...
BioCentury | Oct 13, 2004
Company News

Norak, Purdue GPCR deal

...technology to develop cell lines expressing an orphan GPCR target from Purdue Pharma (Stamford, Conn.). Norak...
BioCentury | Sep 13, 2004
Company News

Norak, Roche deal

...The companies extended for a second year their 2002 deal under which Norak provides ROCZ with...
...with its Transfluor cell lines expressing GPCR targets of interest (see BioCentury, Oct. 7, 2002). Norak...
Items per page:
1 - 10 of 52